Puma Biotechnology
Puma Biotechnology Archives -
Puma Biotech shares slide after glimpse of trial data on cancer drug | Financial Times
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug - TVC News
European Commission Grants Marketing Authorisation for Puma Biotechnology's NERLYNX® (neratinib) for Extended Adjuvant Treatm
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
PUMA Background
JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera | Precision Oncology News
Puma Biotechnology, Inc. 2018 Q2 - Results - Earnings Call Slides (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Puma Biotechnology | Evaluate
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology breast cancer drug approved in EU | S&P Global Market Intelligence
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech victory in neratinib litigation
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology
Puma Biotech to pay PPD founder $22M in defamation suit from proxy fight | Fierce Pharma
